JAGADISHWAR
PHARMACEUTICAL
WORKS LIMITED

CIN : L24232WB1987PLC281952

21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053
Website: jagadishwarpharma.com
E_mail ID: jpwltd@yahoo.com
Phone No.: +91 9163513015

Date: November 13, 2026

Head- Listing & Compliance
Metropolitan Stock Exchange of India Ltd. (MSEI),
205(A), 2nd Floor, Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West),
Mumbai – 400 070

Dear Sir,

Sub: Outcome of the Board Meeting held on today, November 13, 2026

Please note that the Board of Directors of the Company at its meeting held today, which commenced at 02.00 p.m. and concluded at 02.30 p.m. has inter alia transacted the following business:

1. Considered and approved Un-audited Financial Results along with Limited Review Report for the quarter and half year ended September 30, 2026;

2. Considered and approved Statement of Assets and Liabilities for the quarter and half year ended September 30, 2026.

Kindly take the same on your records and acknowledge the receipt.

Thanking You,

For Jagadishwar Pharmaceutical Works Limited

JAGADISHWAR PHARMACEUTICAL WORKS LTD. KOLKATA

Swapan Sarkar
Director
DIN : 05149442

Encl: As above

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232WB1987PLC281952)
21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053
Email: jpwltd@yahoo.com, Website: jagadishwarpharma.com, Tel.: +91 9163513015

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2026

(Rs. In Lacs)

	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	31-03-2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**Income From Operations**						
	(a) Net Sales / Income from Operations (Net of Excise Duty)	-	-	5.981	-	5.981	5.981
	(b) Other Operating Income	10.619	11.863	9.011	22.481	18.088	37.775
	Total Income from Operations	**10.619**	**11.863**	**14.992**	**22.481**	**24.069**	**43.756**
2	**Expenses**						
	(a) Cost of materials consumed	-	-	5.981	-	5.981	-
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	5.981
	(d) Employee benefits expense	0.591	0.591	13.034	1.182	20.353	28.913
	(e) Depreciation and amortisation expense	0.004	0.016	-	0.020	-	0.061
	(f) Other expenses	0.931	3.949	1.208	4.880	5.383	7.782
	Total Expenses	**1.526**	**4.556**	**20.223**	**6.082**	**31.718**	**42.737**
3	**Profit / (Loss) from Operations before other income, finance costs and exceptional items (1-2)**	**9.093**	**7.306**	**(5.231)**	**16.400**	**(7.649)**	**1.019**
4	Other Income	-	-	-	-	-	-
5	**Profit / (Loss) from ordinary activities before finance costs and exceptional items (3-4)**	**9.093**	**7.306**	**(5.231)**	**16.400**	**(7.649)**	**1.019**
6	Finance Costs	-	-	-	-	-	-
7	**Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)**	**9.093**	**7.306**	**(5.231)**	**16.400**	**(7.649)**	**1.019**
8	Exceptional Items	-	-	-	-	-	-
9	**Profit / (Loss) from ordinary activities before tax (7-8)**	**9.093**	**7.306**	**(5.231)**	**16.39962**	**(7.649)**	**1.019**
10	Tax Expense	1.058	1.183	-	2.241	-	0.161
11	**Net Profit / (Loss) from ordinary activities after tax (9-10)**	**8.035**	**6.124**	**(5.231)**	**14.159**	**(7.649)**	**0.858**
12	Extraordinary itesm (net of tax Rs. Nil Lakhs)	-	-	-	-	-	-
13	**Net Profit / (Loss) for the period (11-12)**	**8.035**	**6.124**	**(5.231)**	**14.159**	**(7.649)**	**0.858**
14	Share of Profit / (loss) of associates	-	-	-	-	-	-
15	Minority Interest	-	-	-	-	-	-
16	**Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13-14-15)**	**8.035**	**6.124**	**(5.231)**	**14.159**	**(7.649)**	**0.858**
17	Other Comprehensive Income	-	-	-	-	-	8.080
18	**Total Comprehensive Income**	**8.035**	**6.124**	**(5.231)**	**14.159**	**(7.649)**	**8.938**
19	**Paid-up Equity Share Capital (Face Value of Rs.10/- per Share)**	**2,970.019**	**2,970.019**	**2,970.019**	**2,970.019**	**2,970.019**	**2,970.019**
20	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	**132.338**
21.i	**Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised)**						
	(a) Basic	0.027	0.021	-	0.048	-	0.003
	(b) Diluted	0.027	0.021	-	-	-	0.003
21.ii	**Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised)**						
	(a) Basic	0.027	0.021	-	0.048	-	0.003
	(b) Diluted	0.027	0.021	-	0.048	-	0.003

Notes:

1	The above results are in compliance with Indian Accounting Standards (Ind-AS) notified by the Ministry of Corporate Affairs. The results for the previous periods have been restated as per Ind AS. The standalone financial results of the Company for the Quarter and Half Year ended 30th September, 2026 have been reviewed by the Audit Committee at their meeting held on 13th November, 2026 and have been approved by the Board of Directors at its meeting held on 13th November, 2026.
2	The Statutory Auditors have carried out a "Limited Review" of the above financial results for the Quarter / Half Year ended 30th September, 2026.
3	Previpous period/Year figures have been regrouped/reclassified to make them comparable with those of current period/year.

For Jagadishwar Pharmaceutical Works Limited

JAGADISHWAR PHARMACEUTICAL WORKS LTD. KOLKATA

Swapan Sarkar

Swapan Sarkar
Director
(DIN : 05149442)

Place : Kolkata
Date : 13.11.2026

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232WB1987PLC281952)

21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Standalone Statement of Assets and Liabilities

(Rs. In Lacs)

Sr No	Particulars	Current Half Year ended 30th September, 2026	Previous Year ended 31st March, 2026
		(Unaudited)	(Audited)
A	**EQUITY AND LIABILITIES**		
1	**Shareholders' funds**		
	(a) Share Capital	2,970.02	2,970.02
	(b) Reserves and Surplus	155.44	141.28
	(c) Money received against share warrants	-	-
	Sub-total - Shareholder's funds	**3,125.46**	**3,111.30**
2	**Share Application Money - pending allotment**	-	-
3	**Minority interest**	-	-
4	**Non-Current Liabilities**		
	(a) Long-term borrowings	-	-
	(b) Deferred tax liabilities (net)	-	-
	(c) Other long-term liabilities	-	-
	(d) Long-term provisions	-	-
	Sub-total - Non-Current Liabilities	-	-
5	**Current Liabilities**		
	(a) Short-term borrowings	-	-
	(b) Trade payables	-	-
	(c) Other current liabilities	0.29	0.35
	(d) Short-term provisions	-	-
	Sub-total - Current Liabilities	**0.29**	**0.35**
	TOTAL - EQUITY AND LIABILITIES	**3,125.75**	**3,111.65**
B	**ASSETS**		
1	**Non-Current Assets**		
	(a) Fixed assets	0.02	0.04
	(b) Goodwill on consolidation	-	-
	(c) Non-current investments	1,264.58	1,264.58
	(d) Deferred tax asets (net)	-	-
	(e) Long-term loans and advances	4.79	4.79
	(f) Other non-current assets	-	-
	Sub-total - Non-Current Assets	**1,269.39**	**1,269.41**
2	**Current assets**		
	(a) Current investments	-	-
	(b) Inventories	439.40	439.40
	(c) Trade recivables	-	-
	(d) Cash and cash equivalants	24.67	18.22
	(e) Short-term loans and advances	364.60	357.93
	(f) Other current assets	1,027.69	1,026.69
	Sub-total - Current Assets	**1,856.36**	**1,842.24**
	TOTAL - ASSETS	**3,125.75**	**3,111.65**

For Jagadishwar Pharmaceutical Works Limited

JAGADISHWAR PHARMACEUTICAL WORKS LTD. KOLKATA

Swapan Sarkar

Swapan Sarkar
Director
(DIN : 05149442)

Place: Kolkata
Date : 13.11.2026

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232WB1987PLC281952)

21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Cash Flow Statement for the Half Year ended September 30, 2026

(Rs. In Lacs)

	Half Year Ended 30th September, 2026	Previous Year Ended 31st March, 2026
	(Unaudited)	(Audited)
A. Cash Flow From Operating Activities		
Net Profit before taxation	**16.40**	**1.02**
Add: Depreciation	0.02	0.06
Add: Interest Expenses	-	-
Add: Loss on sale of Fixed Asset	-	-
Add: Loss on sale of Investments	-	-
Less :Interest Income	(22.48)	(36.43)
Operating Profit before Working Capital Changes	**(6.06)**	**(35.34)**
Adjustment for:		
Non Current Financial Assets	-	-
Other Non Current Assets	-	-
Inventories	-	5.98
Trade receivable	-	-
Other Current Assets	(1.00)	(0.60)
Loans and Advances	(6.66)	(67.24)
Trade payable and other Liabilities	-	-
Other Financial Liabilities	-	-
Other Current liabilities	(0.06)	(2.12)
Net Cash inflow from/(outflow) from operating activities	**(13.78)**	**(99.32)**
B. Cash flow from Investing Activities		
Sale Proceeds from fixed Assets	-	-
Sale Proceeds from Investments	-	80.00
Interest received	22.48	36.43
Fixed Assets Purchase	-	-
Income tax	(2.24)	(1.13)
Net Cash inflow from/(outflow) from Investing Activities	**20.24**	**115.30**
C. Cash flow from Financing Activities		
Proceeds from Borrowing	-	-
Interest paid	-	-
Dividend Paid	-	-
Net Cash inflow from/(outflow) from Financing Activities	-	-
Net Increase /(decrease) in cash and Cash Equivalents	**6.46**	**15.97**
Opening Cash and Cash Equivalents	**18.22**	**2.25**
Closing Cash and Cash Equivalents	**24.67**	**18.22**

For Jagadishwar Pharmaceutical Works Limited

JAGADISHWAR PHARMACEUTICAL WORKS LTD. KOLKATA

Swapan Sarkar

Swapan Sarkar
Director
(DIN : 05149442)

Place : Kolkata
Date : 13.11.2026

RAJESH U SHAH & ASSOCIATES
Chartered Accountants

235, Bansdroni Place
Kolkata-700070
Phone : 033-24310375
E-Mail: rs97cal1@rediffmail.com

Review report to Jagadishwar Pharmaceutical Works Limited

We have reviewed the accompanying statement of unaudited financial results of Jagadishwar Pharmaceutical Works Limited (Name of the Company) for the period ended 30th September 2026. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For **Rajesh U Shah & Associates**
Chartered Accountants

RAJESH U SHAH & ASSOCIATES * KOLKATA * Chartered Accountants

Rajesh Shah.

Rajesh Shah
Proprietor
Membership Number: 056550
Firm Regn. No.: 327799E
UDIN: 26056550MNTRCM7118

Place: Kolkata
Date: November 13, 2026